Module
How do we talk to patients about “Stem Cells”?
When presenting human cell and tissue products (HCTPs) to patients, providers should avoid unregulated terms like “stem cells” and instead focus on tissue-specific supplementation for cartilage-based defects, explaining that these products supply collagenic growth factors (like type I, II, and III collagen) that may help the body heal itself at a cellular level—especially when inflammation is controlled. By using FDA-aligned language, discussing patient-specific regenerative capacity, and matching graft complexity to injury severity and age, clinicians can ethically and effectively guide patients through their options.
Module
Regulatory Environment Around Stem Cells — Dispelling Myths
Dr. Martin delivers a critical and detailed overview of the U.S. regulatory landscape surrounding stem cells, emphasizing that using the term “stem cells” in clinical practice is scientifically inaccurate and legally risky. He explains that current compliant use involves human cell and tissue products (HCTPs) like Wharton's Jelly, which are structural allografts meant to supplement local cartilage defects—not regenerate tissue or treat systemic diseases like osteoarthritis, which would constitute unapproved drug claims.
Module
Are Stem Cells a Scam?
Dr. Martin addresses the misconception that “stem cells” are a cure-all, emphasizing that successful regenerative outcomes depend not on magical products but on proper clinical application rooted in scientific understanding—especially of collagenic differentiation. He urges providers to move beyond marketing hype, deepen their knowledge of biologic mechanisms, and practice evidence-based medicine if they want to stay competitive and deliver meaningful patient results.
Module
The basics behind Allogeneic Science
Dr. Martin offers a science-based explanation of how allografts—particularly Wharton's Jelly—contribute to structural support and localized tissue optimization through collagenic signaling. He encourages providers to move beyond the outdated “stem cell” terminology and focus on the well-characterized growth factor profiles found in structural tissue allografts. Dr. Martin also underscores the importance of using these materials within defined, localized applications and cautions against making non-compliant claims related to systemic effects or disease reversal.